Search
Etazolate
go.drugbank.com/drugs/DB05881InvestigationalEHT 0202 is developed to treat neurodegenerative disorders by ExonHit Therapeutics.
Mexiletine
go.drugbank.com/drugs/DB00379ApprovedInvestigationalAntiarrhythmic agent pharmacologically similar to lidocaine. It may have some anticonvulsant properties.
Oxalic Acid
go.drugbank.com/drugs/DB03902ExperimentalIt is produced in the body by metabolism of glyoxylic acid or ascorbic acid. It is not metabolized but excreted in the urine. It is used as an analytical reagent and general reducing agent. [PubChem]
Acamprosate
go.drugbank.com/drugs/DB00659ApprovedInvestigationalIt was first approved by the FDA in 2004 and initially marketed by Forest Laboratories.[L31783] … [A229073] Acamprosate, also known by the brand name Campral, is a drug used for the maintenance of alcohol abstinence.
Synonyms: N-Acetylhomotaurine, N-acetyl homotaurineSR-9009
go.drugbank.com/drugs/DB14013ExperimentalSR-9011 has been demonstrated that it is specifically lethal to cancer cells and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of normal cells or tissues
Neisseria meningitidis group a capsular polysaccharide diphtheria toxoid conjugate antigen
go.drugbank.com/drugs/DB10798ApprovedInvestigationalThe vaccine contains *N. meningitis* serogroup a capsular polysaccharide antigens that are purified and individually conjugated to diphtheria toxoid protein that are extracted from Corynebacterium diphtheriae … Neisseria meningitidis group a capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by *Neisseria
Gantenerumab
go.drugbank.com/drugs/DB12034InvestigationalDespite the clear association of Aβ aggregation with AD, treatments aimed at preventing Aβ aggregation or removing pre-existing Aβ plaques have shown little to no clinical benefit thus far and remain controversial … [A244705, A244710, A244745] Gantenerumab is a fully human IgG1κ monoclonal antibody derived from the MorphoSys HuCAL®-Fab1 phage display library and subsequently optimized by _in vitro_ CDR cassette
Ivosidenib
go.drugbank.com/drugs/DB14568ApprovedInvestigational[L46287] It was fully approved by the EMA in May 2023.[L46596] … [A248745] Ivosidenib was granted accelerated approval by the FDA in July 2018 for the treatment of relapsed of refractory acute myeloid leukemia in adults.
CZEN 002
go.drugbank.com/drugs/DB05479ExperimentalThe antimicrobial activity of CZEN-002 is unique in that it does not depend on direct damage to the microbial membrane. … It appears that CZEN-002 works on a receptor in yeast that has yet to be identified.